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Abstract
Objective: To evaluate the impact that the implementation of therapeutic guidelines has on the empirical treatment of nosocomial pneu-
monia. Methods: A clinical trial, using historical controls and involving current ICU patients who had acquired nosocomial pneumonia, was 
carried out from June of 2002 to June of 2003. All were treated according to therapeutic guidelines developed by the Commission for Noso-
comial Infection Control of the institution (group with intervention). As controls, the medical charts of the patients who acquired nosocomial 
pneumonia between June of 2000 and June of 2001 (group without intervention) were analyzed. Mortality and mean treatment period, 
as well as the length of hospital and ICU stays, were determined for the patients who acquired nosocomial pneumonia. Results: Mortality 
associated with pneumonia was lower in the group treated according to the therapeutic guidelines (26 vs. 53.6%; p = 0.00). As for overall 
mortality, there was no statistically significant difference between the two periods (51 vs. 57.9%; p = 0.37). There was also no difference 
in the type of microorganisms isolated, treatment period, length of hospital stay or length of ICU stay. Conclusion: The implementation of 
therapeutic guidelines for the treatment of nosocomial pneumonia acquired in the ICU can be efficacious in decreasing mortality rates. 
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Introduction
Nosocomial pneumonia is defined as a lower 
respiratory tract infection that affects the lung 
parenchyma and occurs 48 h or more after admis-
sion to the intensive care unit (ICU).(1) Although there 
have been technological advances in ventilatory 
support and the identification of new pathogens, 
as well as in the development of new antimicro-
bial agents and vaccines, ICU-acquired pneumonia 
remains common and severe.(1,2) More than half of 
all antibiotics prescribed in the ICU are for such 
pneumonia.(3) 
The early initiation of appropriate empirical 
treatment is essential to optimizing patient recovery 
and reducing mortality.(1,4) Recent studies suggest 
that the prevalence of multidrug-resistant bacteria 
is high among patients with ICU-acquired pneu-
monia, implying a worse prognosis.(5,6) Prescription 
of antimicrobial agents should follow priorities such 
as severity of the disease, drug efficacy, previous use 
of antibiotics, presence of comorbidities, resistance 
patterns of in-hospital microorganisms, duration of 
hospital stay, epidemiological impact, and costs.(7)
Therefore, in order to guide physicians in the 
treatment of patients with ICU-acquired pneu-
monia and avoid the excessive use of antibiotics, 
with the consequent increase in resistant microor-
ganisms responsible for more severe infections,(8) 
it is important to adopt therapeutic guidelines. 
These therapeutic guidelines should be based on 
the current situation (population and institution), 
evidence-based data, and the experience of health 
professionals specializing in the area.(9)
Despite the relevance of their use and the 
fact that they are widely studied in the literature, 
therapeutic guidelines have yet to gain accept-
ance, because physicians are afraid of losing their 
autonomy, as well as because there are no conclu-
sive data regarding their efficacy.(8) 
The principal objective of this study was to eval-
uate the impact of the use of therapeutic guidelines 
on overall infection-related mortality in patients 
with ICU-acquired pneumonia. Other objectives 
were to evaluate the duration of hospital stays and 
of treatment.
Methods
A clinical trial, with a historical control group, 
was carried out in the adult ICU of a university 
hospital. based on consensus from the American 
Thoracic Society(10) and the Brazilian Thoracic 
Society(11), as well as on frequency and sensitivity 
data for isolated microorganisms, The Comissão 
de Controle de Infecção Hospitalar (CCIH, Cross 
Infection Control Committee) of the State University 
at Londrina University Hospital, developed thera-
peutic guidelines for the treatment of pneumonia 
(Figure 1a, 1b). Severe pneumonia was defined 
using the American Thoracic Society(1) criteria, which 
include two or more of the following: admission to 
ICU; fraction of inspired oxygen higher than 35% or 
requiring mechanical ventilation (MV); progressive 
infiltration detected in X-rays; multilobar pneu-
monia or presence of cavitations; evidence of severe 
sepsis with hypotension or organ dysfunction; use 
of vasopressor agents for more than 4 h; decrease in 
urine production to < 20 mL/h or requiring dialysis. 
When none of these criteria were met, the pneu-
monia was considered mild. When only one was 
met, the pneumonia was considered moderate. The 
following clinical criteria were used to define wors-
ening of the condition or a lack of improvement: 
fever; leukocytosis; purulent secretion; changes 
in the radiological and oxygenation profiles; and 
unresolved organ dysfunction.(1) The treatment 
period recommended in the therapeutic guide-
lines is 14 days. The intravenous antibiotic doses, 
as well as their adjustments for creatinine clearance 
(CrCl) below 10 mL/min, from 10 to 50 mL/min, 
and above 50 mL/min, are described as follows: 
amikacin 15 mg/kg/day (CrCl < 10: 20-30%; CrCl 
10-50: 30-70%; CrCl > 50: 70-100%); cefepime 
1-2 g 12-12 h or 8-8 h (CrCl < 10: 1 g 24-24 h; 
CrCl 10-50: 2 g 12-12 h or 24-24 h; CrCl > 50: 
2 g 8-8 h or 12-12 h); ciprofloxacin 200-400 mg 
12-12 h or 8-8 h (CrCl < 10: 50%; CrCl 10-50: 50-
75%; CrCl > 50: 100%); clindamycin 600 mg 6-6 h 
or 900 mg 8-8 h (CrCl < 10: 100%; CrCl 10-50: 
100%; CrCl > 50: 100%); imipenem 0.5-1 g 8-8 h 
or 6-6 h (CrCl < 10: 0.125-0.25 g 12-12 h; CrCl 10-
50: 0.25 g 6-6 h or 12-12 h; CrCl > 50: 0.25-0.5 g 
8-8 h or 6-6 h); levofloxacin 500 mg/d (CrCl < 10: 
single 500-mg dose followed by 250 mg 48-48 h; 
CrCl 10-50: single 500-mg dose followed by 250 
mg 24-24 h or 48-48 h; CrCl > 50: 100%); mero-
penem 1-2 g 8-8 h (CrCl < 10: 0.5 g 24-24 h; CrCl 
10-50: 1 g 12-12 h; CrCl > 50: 100%); metronida-
zole 500 mg 8-8 h (CrCl < 10: 50%; CrCl 10-50: 
100%; CrCl > 50: 100%); piperacillin/tazobactam 
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4.5 g 8-8 h or 6-6 h (CrCl < 10: 2.25 g 8-8 h; CrCl 
10-50: 2.25 g 6-6 h; CrCl > 50: 100%).
All patients older than 14 years of age and diag-
nosed with nosocomial pneumonia were included 
in the study. The diagnosis was based on chest 
X-rays with new pulmonary infiltrate or evolu-
tion of existing infiltrate and two or more of the 
following criteria established by the Centers for 
Disease Control(12): leukocytosis (>12,000/mm3) or 
leukopenia (<4,000/mm3); fever (>38 °C) or hypo-
thermia (<35 °C); and purulent tracheal secretions. 
Neutropenic patients (leukocytes < 1000 cells/mm3 
or neutrophils < 500 cells/mm3) were excluded, as 
were transplant patients using immunosuppressants, 
patients under corticosteroid treatment for more 
than one month, patients who developed noso-
comial pneumonia at other facilities, and patients 
transferred to other hospitals. 
All patients who acquired pneumonia in this ICU 
between June of 2002 and June of 2003 (interven-
tion period) were included in the study. They were 
monitored until discharge or death. The diagnosis of 
pneumonia and the application of the therapeutic 
guidelines in these patients were conducted by the 
attending intensivist responsible for the case, under 
from the guidance of the CCIH physician.
Data regarding historical controls (patients 
acquiring pneumonia during the nonintervention 
period) were collected through retrospective anal-
ysis of the medical charts of all patients admitted 
to the ICU between June of 2000 and June of 
2001. Those of patients having developed nosoco-
mial pneumonia in the ICU, as diagnosed by the 
attending intensivist, were selected. The retrospec-
tive definition of pneumonia followed the same 
Figure 1 - a) Therapeutic guidelines for stable patients with mild to moderate pneumonia, without mechanical 
ventilation; and b) unstable patients with severe pneumonia. ICU: intensive care unit; COPD: chronic obstructive 
pulmonary disease.
b
Clindamycin or Metronidazole 
(if aspiration) 
(do not associate if in use of 
piperacillin/tazobactam)
Cefepime or Piperacillin/Tazobactam
+/-
Amikacin or Ciprofloxacin
(if there a risk factor for Pseudomonas: MV, 
long period in ICU or hospital, structural 
pulmonary disease, previous antibiotic therapy, 
immunosuppressive therapy, malnutrition).
Vancomycin
Carbapenem
36 h with worsening
36 h with worsening 48 h without improvement
48 h without improvement
a
Cefepime or Piperacillin/Tazobactam
+
Vancomycin
+/-
Amikacin (if there a risk factor for Pseudomonas)
Metronidazole or Clindamycin
(if bronchial aspiration)
36 h with worsening 48 h without improvement
Carbapenem
If there is a risk factor for                sp. (severe chronic disease; COPD; diabetes mellitus; 
immunosuppression; advanced age), + Levofloxacin
Legionella
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Centers for Disease Control criteria,(12) which were 
investigated in the medical charts and in the CCIH 
registration forms. This period was chosen because 
it provided a sample with characteristics similar to 
those of the intervention group, since during June 
of 2001 and June of 2002 administrative problems 
occurred, with changes in the proportion between 
the number of employees in the health professionals 
team and the number of patients, thus creating a 
confounding variable.
Data collected at inclusion were as follows: iden-
tification data - admission dates (hospital and ICU), 
date of pneumonia diagnosis, reason for admission 
to hospital, and reason for admission to ICU; pres-
ence of comorbidities; previous antibiotic therapy 
(type and duration of use); clinical data - arte-
rial blood pressure, pulse, temperature, heart rate, 
and respiratory rate; acute physiology and chronic 
health evaluation II score (APACHE II); previous MV; 
nasogastric tube; use of drugs that alter gastric pH; 
previous surgery; laboratory data - blood workup, 
arterial blood gas analysis, sodium, potassium, creat-
inine, blood culture (two samples), bronchoalveolar 
lavage, quantitative culture for tracheal secretion. 
The bronchoalveolar lavage fluid was collected 
using fiberoptic bronchoscopy and was considered 
positive at ≥ 104 cfu/mL, and quantitative tracheal 
aspirate was considered positive at ≥ 106 cfu/mL.
In the clinical evolution of the intervention 
group, we evaluated the following: fever; quan-
tity and aspect of the tracheal secretion (subjective 
assessment of the multiprofessional team); general 
health status; antimicrobial agents (type and period 
of use); MV and its duration; surgery; chest X-rays 
every 3 days or at shorter intervals when necessary; 
and outcome, defined as discharge (from the ICU 
and from the hospital) or death. In the noninter-
vention group, these variables were investigated 
in medical charts and the specific CCIH forms. In 
this group, the treatment evaluation and the deci-
sions regarding changes in the antibiotic treatment 
regimen were carried out by the attending inten-
sivist together with the physician responsible for the 
CCIH. This was the routine of prescription at the 
time.
Pneumonia-related mortality was defined as 
death in which nosocomial pneumonia was listed 
as the direct cause, and death unrelated to pneu-
monia was defined as death from other causes. 
Maintaining records for pneumonia-related deaths 
and deaths unrelated to pneumonia are part of the 
CCIH routine. A cross-check was performed with 
death certificate data.
The collected data was transferred to the Epi 
Info program, version 3.2 (Feb/2004), in order to 
perform the descriptive and analytical statistical 
analysis. In order to compare the numeric variables, 
the Student’s t-test (normal distribution data) and 
the Mann-Whitney test (non-normal distribution 
data) were used. To compare the categorical vari-
ables, the chi-square test and the Fisher’s exact test 
were used. The Mantel-Haenszel test was used for 
the stratified analysis. The adopted significance level 
was 5% (p < 0.05), and a 95% confidence interval 
was adopted.
This study was approved by the Ethics in 
Research Committee of the State University at 
Londrina University Hospital according to resolution 
CNS 196/96 (process CEP 069/02).
Results
In the nonintervention period, 81 patients 
were analyzed, 12 of which were excluded from 
the study. In the intervention period, 102 patients 
were analyzed, 6 of which were excluded from the 
study, according to the exclusion criteria (Figure 2), 
resulting in a sample of 165 patients analyzed.
Table 1 shows that the demographic and clinical 
characteristics were similar in both groups. In both 
periods, the most common diagnosis at admission 
was skull-brain trauma and cerebral vascular acci-
dent, with no difference between both groups. The 
studied population presented similar severity of the 
disease, observed by APACHE II. The most frequent 
comorbidities were diabetes, chronic obstruc-
tive pulmonary disease, heart failure, and kidney 
failure. 
There was no difference between the two periods 
in terms of the date of pneumonia onset, clinical 
signs in diagnosis, and time on MV. The most 
common clinical signs in the intervention group 
were as follows: tachycardia (in 84.4%); tachypnea 
(in 66.7%); purulent expectoration (in 60.4%); and 
hyperthermia (in 47.9%).
Most pneumonia cases had an early onset. Of 
the 165 patients, 122 (73.9%) were placed on MV 
before the pulmonary infection. The use of MV 
before pneumonia was higher in the intervention 
group (83.3%; p = 0.05). Regarding other risk 
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factors, there was no difference between the two 
groups, except for the H+ proton pump inhibitors, 
which were more often used in the intervention 
period (p = 0.01) (Table 1). 
Most patients in the intervention group (56.3%) 
received antibiotic therapy before the onset of pneu-
monia, and 53.7% received antibiotic therapy during 
the 5 days before the onset of pneumonia. After the 
implementation of the therapeutic guidelines, there 
was a significant decrease in the administration of 
cefepime, clindamycin, amikacin, and ceftriaxone 
(p = 0.00), as well as an increase in the administration 
of vancomycin (p = 0.02), piperacillin/tazobactam 
(p = 0.00), and chloramphenicol (p = 0.02). In 9 of 
the intervention group patients, the first antibiotic 
administered was carbapenem, since these patients 
developed pneumonia while under treatment with 
cefepime or piperacillin/tazobactam for infection 
at another site. The mean treatment period was 
similar in both groups: 16.6 ± 12.2 days (interven-
tion group); and 17.6 ± 15.8 days (nonintervention 
group) (Table 2). 
In the culture of tracheal aspirate, 39% of the 
nonintervention group patients tested positive, 
compared with 47.9% of the intervention group 
patients. Similar microorganisms were found in both 
groups: methicillin-resistant Staphylococcus aureus, 
Pseudomonas aeruginosa, Acinetobacter sp., and 
Stenotrophomonas maltophilia. Bronchoalveolar 
lavage fluid was collected from 13 patients, all in 
the intervention group. There was no significant 
difference between the groups regarding the stay 
in the ICU and hospital. The mean ICU stays were 
18.7 ± 17.2 days (nonintervention period) and 
16.0 ± 12.2 days (intervention period). The mean 
hospital stays were 32 ± 29.9 days (nonintervention 
period) and 26.3 ± 17.3 days (intervention period) 
(Table 3).
Pneumonia-related mortality was lower in the 
group treated according to the therapeutic guide-
lines (p = 0.00). Of the 69 historical control patients, 
40 (57.9%) died, the principal cause of death being 
listed as pneumonia for 37 (53.6%). In the nonin-
tervention period, 29 (42.1%) of the patients were 
discharged from hospital. In the intervention period, 
49 (51%) of the 96 patients died, the principal cause 
of death being listed as pneumonia for 25 (26%). 
Figure 2 - Diagram of patients included in this study and description of mortality rates. ICU: intensive care unit.
Intervention group
June of 2002 to June of 2003
No. of ICU patients = 854
No. of patients included = 102
6 patients excluded: 
2 using immunosuppressants
3 using corticosteroids
1 transferred to another hospital
96 patients studied
Overall mortality: 49 (51%)
Pneumonia-related mortality: 25 (26%)
Nonintervention group
June of 2000 to June of 2001
No. of ICU patients = 731
No. of patients included = 81
12 patients excluded:
2 neutropenic 
3 non-ICU-acquired pneumonia 
3 non-ICU-acquired pneumonia 
2 not meeting clinical criteria 
4 using corticosteroids
69 patients studied
Overall mortality: 40 (57.9%)
Pneumonia-related mortality: 37 (53.6%)
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Table 1 - Clinical characteristics of patients with ICU-acquired pneumonia at the State University at Londrina University 
Hospital according to the implementation of therapeutic guidelines. Londrina, Brazil, 2004. 
Characteristic Nonintervention (n = 69) Intervention (n = 96) p value
Age (years) 53.6 ± 19.6 52.0 ± 21.6 0.70
Stratified age
Up to 50 years 29 (42.0%) 43 (44.8%) 0.84
>50 40 (58.0%) 53 (55.2%)
Gender
Male 42 (60.9%) 61 (63.5%) 0.85
Female 27 (39.1%) 35 (36.5%)
Cause of admission to ICU
SBT 15 (21.7%) 30 (31.2%) 0.66
CVA 10 (14.5%) 13 (13.5%) -
Postoperative recovery 20 (29.0%) 22 (22.9%) 0.48
Hemodynamic instability 12 (17.4%) 10 (10.4%) 0.28
Respiratory failure 12 (17.4%) 2 (2.1%) 0.00
CHF 10 (14.5%) 8 (8.3%) 0.31
Comorbidity
No 32 (46.4%) 32 (33.3%) 0.12
Yes 37 (53.6%) 64 (66.7%)
Type of comorbidity
Diabetes 11 (15.9%) 16 (16.7%) 0.93
COPD 10 (14.5%) 10 (10.4%) 0.58
Heart failure 10 (14.5%) 15 (15.6%) 0.98
Kidney failure 10 (14.5%) 9 (9.4%) 0.46
CVA 6 (8.7%) 18 (18.8%) 0.11
Other 23 (33.3%) 44 (45.8%) 0.14
Surgical intervention
Elective 16 (23.5%) 18 (18.8%) 0.58
Emergency before pneumonia 14 (20.6%) 34 (35.8%) 0.05
Emergency after pneumonia 10 (14.7%) 7 (7.3%) 0.20
APACHE II 30.0 ± 6.9 29.2 ± 8.8 0.22
Time before diagnosis (days)
Early (≤4) 51 (73.9%) 71 (74.0%) 0.86
Late (>4) 18 (26.1%) 25 (26.0%)
Clinical signs at diagnosis
Tachycardia 56 (81.2%) 81 (84.4%) 0.74
Purulent expectoration 41 (59.4%) 58 (60.4%) 0.97
Tachypnea 38 (55.1%) 64 (66.7%) 0.18
Hyperthermia 29 (42.0%) 46 (47.9%) 0.55
Hypotension 20 (29.0%) 23 (24.0%) 0.58
Hypothermia 7 (10.1%) 5 (5.2%) 0.37
Extrapulmonary infection 3 (4.3%) 13 (13.5%) 0.09
Bronchial aspiration 2 (2.9%) 4 (4.2%) 0.99
Mechanical Ventilation
Before pneumonia 48 (69.6%) 80 (83.3%) 0.05
After pneumonia 10 (14.5%) 7 (7.3%) 0.21
Time on mechanical ventilation (days) 10.1 ± 9.9 11.0 ± 9.1 0.47
Other risk factors
Nasogastric tube 37 (53.6%) 47 (49.0%) 0.66
H2 blocker 45 (65.2%) 59 (51.5%) 0.74
H+ proton pump inhibitor 10 (14.5%) 32 (33.3%) 0.01
ICU: intensive care unit; SBT: skull-brain trauma; CVA: cerebral vascular accident; CHF: congestive heart failure; COPD: chronic 
obstructive pulmonary disease; APACHE II: Acute Physiology and Chronic Health Evaluation II.
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In the intervention period, 47 patients (49%) were 
discharged from the hospital (Table 3).
Discussion
In the present study, the implementation of 
therapeutic guidelines for the empirical treatment 
of nosocomial pneumonia reduced mortality in 
ICU patients. There were no reductions in treat-
ment duration, ICU stay, or hospital stay. However, 
these results should be interpreted with caution. 
In studies evaluating two or more different 
periods, confounding variables can interfere with 
the results.(13) Such confounding variables include 
changes in medical and nursing staff, in the quality 
of invasive procedures, in the profile of in-hospital 
patients, in measures for prevention and control 
of cross infections, in the level of resistance of 
microorganisms, and in policies regarding the use 
of antimicrobial agents. Predisposing factors for 
pneumonia (age, comorbidities, MV, nasogastric 
tube, and drugs that change the gastric pH), as well 
as innovations in surgical techniques, can also be 
considered confounding variables.
Ventilator-associated pneumonia (VAP) is the 
most common and severe cross infection acquired 
in ICUs.(1,2) Among all cross infections, it is consid-
ered the main cause of death, ranging from 
20 up to 70%. Mortality can be associated with 
comorbidities and not directly with pneumonia. 
However, this is a controversial issue and contradic-
tory results have been reported.(14) The mortality rate 
is lower when the disease is caused by drug-sensi-
tive bacteria. Among such bacteria, P. aeruginosa 
and A. baumannii have been associated with the 
worst prognosis.
The use of MV increases the risk of pneumonia 
by 6 to 21 times. As a consequence of this high 
Table 2 - Characteristics of the patients studied as a function of the antibiotics used, and duration of treatment 
according to implementation of the therapeutic guidelines. Londrina, Brazil, 2004.
Characteristic Nonintervention (n = 69) Intervention (n = 96) p value
Previous use of antibiotics
No 39 (56.5%) 42 (43.8%) 0.14
Yes 30 (43.5%) 54 (56.3%)
Duration of previous use
of antibiotics (days)
1-5 19 (63.3%) 29 (53.7%) 0.68
6-10 6 (20.0%) 13 (24.1%)
>10 5 (16.7%) 12 (22.2%)
Antibiotics used for treatment
Cefepime 53 (76.8%) 39 (40.6%) 0.00
Clindamycin 51 (73.9%) 7 (7.3%) 0.00
Vancomycin 35 (50.7%) 67 (69.8%) 0.02
Amikacin 32 (46.4%) 12 (12.5%) 0.00
Ceftriaxone 20 (29.0%) 1 (1.0%) 0.00
Imipenem 14 (20.3%) 23 (24.0%) 0.71
Meropenem 10 (14.5%) 22 (22.9%) 0.24
Metronidazole 10 (14.5%) 4 (4.2%) 0.03
Levofloxacin
Piperacillin/tazobactam
4 (5.8%)
3 (4.3%)
20 (20.8%)
48 (50.0%)
0.01
0.00
Ciprofloxacin 3 (4.3%) 6 (6.3%) 0.85
Chloramphenicol 1 (1.4%) 12 (12.5%) 0.02
Duration of treatment (days) 17.6 ± 15.8 16.6 ± 12.2 0.88
Stratified duration of
treatment (days)
≤7 19 (27.5%) 26 (27.1%) 0.93
8-14 18 (26.1%) 23 (24.0%)
>14 32 (46.4%) 47 (49.0%)
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risk, most studies of pneumonia now focus on its 
association with this procedure.(1,15) In the present 
study, patients treated according to the thera-
peutic guidelines were more often placed on MV 
(p = 0.05). This could explain the isolation of 
multidrug-resistant bacteria. Most of the patients 
(74%) developed early pneumonia (within 4 days). 
Studies report that early pneumonia is common in 
patients with brain trauma.(16,17) It has also been 
reported that the most susceptible individuals are 
those infected with S. aureus,(18,19) with pulmo-
nary aspiration,(20) or submitted to sedation.(17) In 
polytraumatized patients, the frequency of VAP 
ranges from 6 to 45%. Patients with acute cerebral 
vascular accident are considered to be at a high risk 
of acquiring pneumonia in the ICU, and intuba-
tion is one of the most influential factors.(21) In the 
present study, neurological alterations constituted 
the principal reason for ICU admission. The most 
frequent diagnoses for ICU admission were cranial 
trauma, cerebral vascular accident, and polytrauma. 
Therefore, these patients can be considered more 
susceptible to early pneumonia.
The profile of the bacteria isolated is more 
consistent with pneumonias acquired in a later 
phase, which can be partially explained by the fact 
that approximately half of the patients presented 
negative cultures due to the previous use of anti-
biotics. In the last ten years, changes in the 
microbiology of infections have been taking place, 
especially in terms of multidrug-resistance of 
hospital pathogens. The increase in the numbers of 
such microorganisms is primarily found in ICUs(1,22) 
as a result of the intense selective pressure imposed 
by the antibiotics used in these facilities. There 
is evidence that infections caused by multidrug-
resistant pathogens have worse prognoses due to 
the delay in initiating the appropriate treatment. 
The P. aeruginosa and A. baumannii strains have 
become producers of cephalosporinases, which are 
resistant to piperacillin/tazobactam, aztreonam, 
and ceftazidime. Klebsiella pneumoniae and other 
enterobacteria are also becoming producers of 
extended-spectrum beta-lactamases, conferring 
resistance on third-generation cephalosporins.(23) 
Another multidrug-resistant, gram-negative bacillus 
is S. maltophilia, which was isolated in 11.5% of 
cultures of this study. In ICU patients, S. aureus is 
increasingly present, especially in those submitted 
to MV for a prolonged period. Therefore, the VAP 
microbiology is increasingly involving multidrug-
resistant pathogens, posing difficulties to the 
treatment.(1,24)
The microorganisms found were the same in 
both periods. However, the frequency was lower in 
the nonintervention group, since there were fewer 
cultures performed in the nonintervention period. 
Although some authors have reported that tracheal 
Table 3 - Patients with ICU-acquired pneumonia, according to length of ICU stay, length of hospital stay, and 
outcome. Londrina, Brazil, 2004.
Hospital stay
(days)
Nonintervention  
(n = 69)
Intervention  
(n = 96)
p value
ICU stay (days) 18.7 ± 17.2 16.0 ± 12.2 0.66
Stratified ICU stay (days)
1-10 29 (42.0%) 39 (40.6%) 0.71
11-20 20 (29.0%) 35 (36.5%)
21-30 10 (14.5%) 10 (10.4%)
>30 10 (14.5%) 12 (12.5%)
Hospital stay (days) 32.0 ± 29.9 26.3 ± 17.3 0.49
Stratified hospital stay (days)  
1-10 14 (20.3%) 18 (18.8%) 0.36
11-20 17 (24.6%) 25 (26.0%)
21-30 11 (15.9%) 25 (26.0%)
>30 27 (39.1%) 28 (29.2%)
Outcome
Overall mortality 40 (57.9%) 49 (51.0%) 0.37
Pneumonia-related mortality 37 (53.6%) 25 (26.0%) 0.00
ICU: intensive care unit.
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colonization by potentially pathogenic pathogens 
typically precedes pneumonia, this does not occur in 
all patients. Some authors(25,26) defend the hypoth-
esis that when colonization by potentially resistant 
microorganisms (such as methicillin-resistant 
S. aureus or K. pneumoniae) that produce extended-
spectrum beta-lactamases or other enterobacteria 
occurs, the risk of infection with these pathogens 
is high.
The number of days on MV and the adminis-
tration of antibiotics before the development of 
pneumonia are independent risk factors associated 
with the development of pneumonia caused by 
multidrug-resistant microorganisms.(27) These facts 
could explain the presence of resistant strains in 
the present study, considering that 56.3% of the 
patients had previously been treated with antibi-
otics, and 83.3% had been submitted to MV before 
the development of infection. The presence of 
microorganisms that are resistant to antimicrobial 
agents is common in severe patients. Therefore, it 
is important that the first empirical treatment be 
broad-spectrum therapy.
Regarding the optimum period for treatment of 
nosocomial pneumonia, there is still no consensus. 
The use of antibiotics for a prolonged period has an 
effect on bacterial ecology and antibiotic toxicity, as 
well as increasing the cost of treatment. The treat-
ment period proposed by the American Thoracic 
Society(10) is 14 days, or 21 days in the following situ-
ations, in which there is a risk of treatment failure: 
multilobar involvement; malnutrition; cavitation; 
necrotizing pneumonia; and pneumonia caused 
by Acinetobacter sp. or P. aeruginosa. When the 
pathogen is S. aureus or Haemophilus influenzae, 
the minimum period should be 7 to 10 days. It 
has been reported that shorter periods (8 days) are 
sufficient to treat VAP.(28) However, shorter treat-
ment periods can increase the rate of recurrence, 
and longer periods of observation are therefore 
necessary. Short-duration treatment regimens are 
safe and can reduce the emergence of multidrug-
resistant bacteria.(29) In the present study, there was 
no difference between the two groups in terms of 
treatment duration. This is likely attributable to the 
fact that, in both periods, the treatment duration 
was in compliance with the recommendation of the 
American Thoracic Society.(10) 
For these reasons, strategies to improve the 
administration of antimicrobial agents, reduce 
bacterial resistance, and improve survival have 
been developed. The use of therapeutic guidelines 
is one alternative. In one study(27) carried out in 
two periods (before and after the implementation 
of therapeutic guidelines) and aimed at improving 
the use of antimicrobial agents, the authors did not 
observe differences in mortality rates. However, in 
the group treated according to the guidelines, the 
treatment was more effective (p < 0.00) and of a 
shorter duration (p < 0.00). In a recent publication, 
the American Thoracic Society(1) recommended the 
administration of early and appropriate antibiotic 
therapy as indispensable to avoid its excessive use, 
reducing the therapeutic spectrum when the etiology 
and the antibiogram allow it, as well as reducing the 
duration of treatment as much as possible.
Other authors(30) studied compliance with the 
protocol recommended by the Brazilian Consensus 
on Pneumonia(11) for the treatment of commu-
nity-acquired pneumonias in elderly individuals. 
The authors found compliance with the protocol 
in 61.1% of the cases. Differences in the length of 
hospital stay, treatment costs, time to clinical stabi-
lization, and index of severity of pneumonia were 
not observed between the two groups (those treated 
according to the consensus and those not treated 
according to the consensus). Regarding mortality, 
those with a higher index of severity (IV and V) 
presented higher mortality rates than did those 
who were not treated according to the consensus 
(p = 0.04).
There was, in the present study, ample compli-
ance with the protocol, since the routine in this 
sector is to monitor patients closely and to follow 
the CCIH protocols in all patients being treated with 
antibiotic therapy.
Other studies have shown that a delay in initi-
ating treatment increases mortality.(1,4,7) Therapeutic 
guidelines have been developed as an efficient 
means of avoiding the unnecessary use of antimi-
crobial agents and decreasing bacterial resistance. 
However, until now, few studies of the effects that 
implementing such guidelines has on mortality rates 
have been conducted. It is important to empha-
size that every institution should establish its own 
protocol according to the prevalence and sensitivity 
patterns of the local microorganisms.
The results of the present study suggest that 
the implementation of therapeutic guidelines for 
the treatment of ICU-acquired pneumonia can be 
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effective in lowering the rates of pneumonia-related 
mortality. However, the implementation of the 
guidelines had no effect on treatment duration, time 
spent in the ICU, or the length of hospital stays.
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